Randomized, Double-Blind, Dose-Ranging Study of TAK-875, a Novel GPR40 Agonist, in Japanese Patients With Inadequately Controlled Type 2 Diabetes

February 2013
Diabetes Care;Feb2013, Vol. 36 Issue 2, p245
Academic Journal
OBJECTIVE--Assessment of the efficacy and safety of TAK-875 (a novel GPR40 agonist) in Japanese patients with type 2 diabetes inadequately controlled by diet/exercise. RESEARCH DESIGN AND METHODS--This was a phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled, 12-week dose-ranging evaluation of TAK-875 (6.25-200mg once daily)with the primary end point of change in A1C at week 12. A nonblinded group received 1 mg glimepiride once daily as an active control. RESULTS--A total of 396 patients were randomized to receive TAK-875 (n = 299), placebo (n = 48), or glimepiride (n = 49). The least square mean changes in A1C at week 12 from baseline were as follows: 0.09% in the placebo group; -0.54, -0.67, -0.88, -1.27, -1.29, and -1.40% in the 6.25-, 12.5-, 25-, 50-, 100-, and 200-mg TAK-875 groups, respectively; and -1.32% in the 1-mg glimepiride group. All TAK-875 groups had statistically significant reductions in A1C compared with placebo (P < 0.0001), and those receiving ≥50 mg TAK-875 achieved reductions in A1C equivalent to those with glimepiride. Results for other glycemic parameters, including improvements during a meal tolerance test, mirrored these positive findings with TAK-875. There were no significant differences in incidence of adverse events among the groups and no dose-dependent changes in tolerability. Hypoglycemic episodeswere reported in 0.7% of patients in the TAK-875 groups and in 4.1% of the glimepiride group. CONCLUSIONSdTAK-875 produced clinically and statistically significant improvements in glycemic control in patients with type 2 diabetes inadequately controlled by diet and exercise, and it was well tolerated with a lower propensity to cause hypoglycemia.


Related Articles

  • Effect of camel milk on glycemic control and insulin requirement in patients with type 1 diabetes: 2-years randomized controlled trial. Agrawal, R P; Jain, S; Shah, S; Chopra, A; Agarwal, V // European Journal of Clinical Nutrition;Sep2011, Vol. 65 Issue 9, p1048 

    Background/Objectives:Hypoglycemic effect of camel milk supplementation in experimental rat model and significant reduction in doses of insulin in type 1 diabetic patients have been observed in our previous studies. This long-term study was undertaken to assess the efficacy, safety and...

  • A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. Tilden, Dominic P.; Mariz, Segundo; O'Bryan-Tear, Gillies; Bottomley, Julia; Diamantopoulos, Alexander // PharmacoEconomics;2007, Vol. 25 Issue 1, p39 

    Introduction: Adding pioglitazone or rosiglitazone to existing therapy are alternative treatment options for patients with type 2 diabetes mellitus who have insufficient glycaemic control while receiving the maximal tolerated dose of metformin monotherapy. Our objective was to...

  • Antidiabetic Plants of Iran. Shojaii, Asie; Dabaghian, Fataneh Hashem; Goushegir, Ashrafeddin; Fard, Mehri Abdollahi // Acta Medica Iranica;2011, Vol. 49 Issue 10, p637 

    Abstract- To identify the antidiabetic plants of Iran, a systematic review of the published literature on the efficacy of Iranian medicinal plant for glucose control in patients with type 2 diabetes mellitus was conducted. We performed an electronic literature search of MEDLINE, Science Direct,...

  • A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers. Wilding, John P.H.; Norwood, Paul; T'Joen, Caroline; Bastien, Arnaud; List, James F.; Fiedorek, Fred T. // Diabetes Care;Sep2009, Vol. 32 Issue 9, p1656 

    OBJECTIVE -- To determine whether dapagliflozin, which selectively inhibits renal glucose reabsorption, lowers hyperglycemia in patients with type 2 diabetes that is poorly controlled with high insulin doses plus oral antidiabetic agents (OADs). RESEARCH DESIGN AND METHODS -- This was a...

  • The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone. Defronzo, Ralph A.; Hissa, Miguel N.; Garber, Alan J.; Gross, Jorge Luiz; Duan, Raina Yuyan; Ravichandran, Shoba; Chen, Roland S. // Diabetes Care;Sep2009, Vol. 32 Issue 9, p1649 

    OBJECTIVE -- This 24-week trial assessed the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes with inadequate glycemic control with metformin alone. RESEARCH DESIGN AND METHODS -- This was a randomized, double-blind, placebo-controlled study of saxagliptin...

  • The effects of probiotic bacteria on glycaemic control in overweight men and women: a randomised controlled trial. Ivey, K L; Hodgson, J M; Kerr, D A; Lewis, J R; Thompson, P L; Prince, R L // European Journal of Clinical Nutrition;Apr2014, Vol. 68 Issue 4, p447 

    Background/Objectives:Evidence from animal and in vitro models suggest a role of probiotic bacteria in improving glycaemic control and delaying the onset of type 2 diabetes. However, the evidence from controlled trials in humans is limited. The objective was to determine if the probiotic...

  • Effect of pitavastatin in different SLCO1B1 backgrounds on repaglinide pharmacokinetics and pharmacodynamics in healthy Chinese males. Jie Zhu; Min Song; Hong-Yi Tan; Li-Hua Huang; Zhi-Jun Huang; Chang Liu; Zhi-Min Fu; Yuan-Yuan Huang; Zhi-Rong Tan; Xiao-Ping Chen; Hong Yuan; Guo-Ping Yang // Pakistan Journal of Pharmaceutical Sciences;May2013, Vol. 26 Issue 3, p577 

    The effect of pitavastatin and SLCO1B1 genetic background on the pharmacokinetic and pharmacodynamic properties of repaglinide was investigated. In this randomized, placebo-controlled, crossover study, twelve healthy Chinese males were administered with pitavastatin 4 mg/d or the placebo for 5 d...

  • High-Dose Vitamin D Supplementation in People With Prediabetes and Hypovitaminosis D. DAVIDSON, MAYER B.; DURAN, PETRA; LEE, MARTIN L.; FRIEDMAN, THEODORE C. // Diabetes Care;Feb2013, Vol. 36 Issue 2, p260 

    OBJECTIVE--Low vitamin D levels predict the development of diabetes. This double-blind, randomized, control study in subjects with prediabetes and hypovitaminosis D evaluated whether high doses of vitamin D for 1 year affected insulin secretion, insulin sensitivity, and the development of...

  • weight-reducing agents improve glycaemic control and reduce progression to diabetes. Berry, Diane // Evidence Based Nursing;Apr2009, Vol. 12 Issue 2, p8 

    The article focuses on randomised, double-blind placebo controlled trials which examined whether weight-reducing agents could affect glycaemic parameters and risk of type two diabetes in predisposed patients. These trials evaluated drug therapy and reduced-calorie diets. Included in the outcomes...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics